{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:15:05Z","timestamp":1787775305132,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","award":["TYH2025146"],"award-info":[{"award-number":["TYH2025146"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","award":["WBS4708719"],"award-info":[{"award-number":["WBS4708719"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104480","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:25:21Z","timestamp":1768004721000},"page":"104480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the new European risk classification for endometrial carcinoma: a cohort study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-2367","authenticated-orcid":false,"given":"Mikko","family":"Loukovaara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-5099","authenticated-orcid":false,"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7447","key":"10.1016\/j.ijgc.2026.104480_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104480_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104480_bib3","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104480_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ijgc.2026.104480_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2022.12.019","article-title":"The continuing evolution of endometrial carcinoma molecular classification: risk stratification within the no specific molecular profile (NSMP) subtype","volume":"171","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104480_bib6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/IGC.0000000000000801","article-title":"L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer","volume":"26","author":"Pasanen","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104480_bib7","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104480_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104480_bib9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104480_bib10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2026.104480_bib11","series-title":"International Agency for Research on Cancer","article-title":"Female Genital Tumours","year":"2020"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104480_bib12","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104480_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.ijgc.2026.104480_bib14","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"The PORTEC study group. Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"27","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2026.104480_bib15","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"L\u00e9on-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104480_bib16","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/cncr.20645","article-title":"Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?","volume":"101","author":"Boruta","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104480_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104480_bib18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","volume":"155","author":"Raffone","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104480_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100048","article-title":"Clinicopathologic stratification demonstrates survival differences between endometrial carcinomas with mismatch repair deficiency and no specific molecular profile: a cohort study","volume":"35","author":"Loukovaara","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104480_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ygyno.2025.04.589","article-title":"Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer","volume":"197","author":"Loukovaara","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104480_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104480_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2019.06.012","article-title":"Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: towards early personalized patient management","volume":"154","author":"Abdulfatah","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104480_bib23","doi-asserted-by":"crossref","first-page":"543.e1","DOI":"10.1016\/j.ajog.2008.04.043","article-title":"GATA3 expression in estrogen receptor \u03b1-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival","volume":"199","author":"Engelsen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104480_bib24","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.ygyno.2019.02.027","article-title":"Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells","volume":"153","author":"Bogani","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ijgc.2026.104480_bib25","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104480_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:23:58Z","timestamp":1785356638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1048891X26000125"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104480","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the new European risk classification for endometrial carcinoma: a cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104480"}}